Analgesics and 5-aminosalicylic acid

  • Monique M. Elseviers
  • Marc E. De Broe

Classic analgesic nephropathy is a slowly progressive disease resulting from the daily use for many years of analgesic mixtures containing at least two antipyretics, anilides and salicylates, and usually caffeine or codeine (or both). The nephropathy is characterized by renal papillary necrosis/calcifications and chronic interstitial nephritis, with an insidious progression to renal failure, sometimes in association with transitional-cell carcinoma of the uroepithelium [1-10]. This type of nephropathy has never been described after the intake of single analgesic substances. Analgesic nephropathy is a facultative part of a broad spectrum of clinical findings that is summarized as ‘analgesic syndrome’ (see below). Historically, these analgesic mixtures most frequently contained phenacetin in combination with a further analgesic and a centrally acting agent such as caffeine or codeine, which may lead to psychological dependence [11-15].


Inflammatory Bowel Disease Nephrol Dial Transplant Analgesic Consumption United States Renal Data System Analgesic Nephropathy 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Spuehler O, Zollinger HU. Die chronisch-interstitielle Nephritis. Zeitschr Klin Medizin 1953; 151: 1-50.Google Scholar
  2. 2.
    Gloor F. Die doppelseitige chronische nichtobstruktive interstitielle Nephritis. Ergebnisse der allgemeinen Pathologie und Pathologischen Anatomie 1961; 41: 63-207.PubMedGoogle Scholar
  3. 3.
    Burry AF, de Jersey P, Weedon D. Phenacetin and renal papillary necrosis: results of a prospective autopsy investigation. Med J Australia 1966; 53: 873-879.Google Scholar
  4. 4.
    Kincaid-Smith P. Pathogenesis of the renal lesion associated with the abuse of analgesics. Lancet 1967; i: 859-862.Google Scholar
  5. 5.
    Kincaid-Smith P, Nanra RS. Lithium-induced and analgesic-induced renal diseases. In: Diseases of the kidney, 5th edition. Schrier RW, Gottschalk CW (editors). Little Brown, Boston 1993; p. 1099-1129.Google Scholar
  6. 6.
    Mihatsch MJ, Torhorst J, Amsler B, Zollinger HU. Capillarosclerosis of the lower urinary tract in analgesic (phenacetin) abuse. Virchows Archiv A. Pathol Anat Histol 1978; 381: 41-47.Google Scholar
  7. 7.
    Henrich WL, Agodoa LE, Barrett B, Bennett WM, Blantz RC, Buckalew VM Jr, D’Agati VD, De Broe ME, Duggin GG, Eknoyan G. Analgesics and the kidney: summary and recommendations to the Scientific Advisory Board of the National Kidney Foundation from an Ad Hoc Committee of the National Kidney Foundation. Am J Kidney Dis 1996; 27(1): 162-165.PubMedGoogle Scholar
  8. 8.
    De Broe ME, Elseviers MM, Bengtsson U, Mihatsch MJ, Molzahn M, Pommer W, Ritz E, Schwarz A. Analgesic nephropathy. Nephrol Dial Transplant 1996; 11: 2407-2408.PubMedGoogle Scholar
  9. 9.
    Duggin GG. Combination analgesic-induced kidney disease: the Australian experience. Am J Kidney Dis 1996; 28 (suppl 1): S39-S47.PubMedGoogle Scholar
  10. 10.
    De Broe ME, Elseviers MM. Analgesic nephropathy. N Engl J Med 1998; 338: 446-452.PubMedGoogle Scholar
  11. 11.
    Haschek H (editor). International symposium on problems of phenacetin abuse. Egermann, Vienna 1973.Google Scholar
  12. 12.
    Gsell O. Nephropathie durch Analgetika. Ergebnisse der inneren Medizin und Kinderheilkunde 1974; 35: 68-175.Google Scholar
  13. 13.
    Carro-Ciampi G. Phenacetin abuse: a review. Toxicology 1978; 10: 311-339.PubMedGoogle Scholar
  14. 14.
    Prescott LF. Analgesic nephropathy: a reassessment of the role of phenacetin and other analgesics. Drugs 1982; 23: 75-149.PubMedGoogle Scholar
  15. 15.
    Kincaid-Smith P. Effects of non-narcotic analgesics on the kidney. Drugs 1986; 42(4): 109-128.Google Scholar
  16. 16.
    Sandler DP, Smith JC, Weinberg CR, Buckalew VM Jr, Dennis VW, Blythe WB, Burgess WP. Analgesic use and chronic renal disease. N Engl J Med 1989; 320(19): 1238-1243.PubMedGoogle Scholar
  17. 17.
    Sandler DP, Burr FR, Weinberg CS. Nonsteroidal anti-inflammatory drugs and the risk for chronic renal disease. Ann Int Med 1991; 115(3): 165-172.PubMedGoogle Scholar
  18. 18.
    Morlans M, Laporte JR, Vidal X, Cabeza D, Stolley PD. End-stage renal disease and non-narcotic analgesics: a case-control study. Br J Clin Pharmacol 1990; 30(5): 717-723.PubMedGoogle Scholar
  19. 19.
    Pommer W. Clinical presentation of analgesic-induced nephropathy. In: Analgesic and NSAID-induced kidney disease. Stewart JH (editor). Oxford University Press, Oxford 1993; p. 108-118.Google Scholar
  20. 20.
    Perneger TV, Whelton PK, Klag MJ. Risk of kidney failure associated with the use of acetaminophen, aspirin, and nonsteroidal antiinflammatory drugs. N Engl J Med 1994; 331: 1675-1679.PubMedGoogle Scholar
  21. 21.
    Fored CM, Ejerblad E, Lindblad P, Fryzek JP, Dickman PW, Signobello LB, Lipworth L, Elinder CG, Blot WJ, McLaughlin JK, Zack MM, Nyrén O. Acetaminophen, aspirin, and chronic renal failure. N Engl J Med 2001; 345: 1801-1808.PubMedGoogle Scholar
  22. 22.
    Larsen K, Moller CE. A renal lesion caused by abuse of phenacetin. Acta Med Scand 1959; 164: 53-71.PubMedGoogle Scholar
  23. 23.
    Jacobs LA, Morris JG. Renal papillary necrosis and the abuse of phenacetin. Med J Australia 1962; 2(14): 531-538.Google Scholar
  24. 24.
    Grimlund K. Phenacetin and renal damage at a Swedish factory. Acta Med Scan 1963; 174 (suppl 405): 1-26.Google Scholar
  25. 25.
    Azad Khan AK, iris J, Truelove SC. An experiment to determine the active therapeutic moiety of sulphasalazine. Lancet 1977; 1: 892-895.Google Scholar
  26. 26.
    World MJ, Stevens PE, Ashton MA, Rainford DJ. Mesalazine-associated interstit ial nephritis. Nephrol Dial Transplant 1996; 11: 614-621.PubMedGoogle Scholar
  27. 27.
    De Broe ME, Stolear JC, Nouwen EJ, Elseviers MM. 5-Aminosalicylic acid (5-ASA) and chronic tubulo-interstitial nephritis in patients with chronic inflammatory bowel disease: is there a link ? Nephrol Dial Transplant 1997; 12: 1839-1841.PubMedGoogle Scholar
  28. 28.
    Stolear JC, Georges B, Gossun A, Ros Ph, Nouwen EJ, De Broe ME. Néphrite interstitiëlle associée à la Mésalazine. Confrontations anatomo-cliniques en pathologie renale et vasculaire; Hôpital Tenon, Paris, 10 Janvier 1996.Google Scholar
  29. 29.
    Murray RM. Analgesic nephropathy: removal of phenacetin from proprietary analgesics. Brit Med J 1972; 4: 131-132.PubMedGoogle Scholar
  30. 30.
    Nanra RS, Stuart-Taylor J, De Leon AH, White KH. Analgesic nephropathy: etiology, clinical syndrome, and clinicopathologic correlation in Australia. Kidney Int 1978; 13: 79-92.PubMedGoogle Scholar
  31. 31.
    Schwarz A, Kunzendorf U, Keller F, Offerman G. Progression of renal failure in analgesic-associated nephropathy. Nephron 1989; 53: 244-249.PubMedGoogle Scholar
  32. 32.
    Hauser AC, Derfler K, Balcke P. Progression of renal insufficiency in analgesic nephropathy: Impact of continuous drug abuse. J Clin Epidemiol 1991; 44: 53-56.Google Scholar
  33. 33.
    McCredie M, Stewart JH, Mahony JF. Is phenacetin responsible for analgesic nephropathy in New South Wales ? Clin Nephrol 1982; 17(3): 134-140.PubMedGoogle Scholar
  34. 34.
    Murray TG, Stolley PD, Anthony JC, Schinnar R, Hepler-Smith E, Jeffreys JL. Epidemiologic study of regular analgesic use and end-stage renal disease. Arch Intern Med 1983; 143: 1687-1693.PubMedGoogle Scholar
  35. 35.
    Pommer W, Glaeske G, Molzahn M. The analgesic problem in the Federal Republic of Germany: analgesic consumption, frequency of analgesic nephropathy and regional differences. Clin Nephrol 1986; 26: 273-278.PubMedGoogle Scholar
  36. 36.
    Pommer W, Bronder E, Greiser E, Helmert U, Jesdinsky HJ, Klimpel A, Borner K, Mohlzahn M. Regular analgesic intake and the risk of end-stage renal failure. Am J Nephrol 1989; 9: 403-412.PubMedGoogle Scholar
  37. 37.
    Ibáñez L, Morlans M, Vidal X, Martínez MJ, Laporte JR. Case-control study of regular analgesic and nonsteroidal anti-inflammatory use and end-stage renal disease. Kidney Int 2005; 67(6): 2393-8.PubMedGoogle Scholar
  38. 38.
    van der Woude FJ, Heinemann LA, Graf H, Lewis M, Moehner S, Assmann A, Kuhl-Habich D. Analgesics use and ESRD in younger age: a case-control study. BMC Nephrol 2007; 8(1): 15.PubMedGoogle Scholar
  39. 39.
    Dubach UC, Rosner B, Pfister E. Epidemiologic study of abuse of analgesics containing phenacetin. Renal morbidity and mortality (1968-1979). N Engl J Med 1983; 308: 357-362.PubMedCrossRefGoogle Scholar
  40. 40.
    Elseviers MM, De Broe ME. A long-term prospective controlled study of analgesic abuse in Belgium. Kidney Int 1995; 48: 1912-1919.PubMedGoogle Scholar
  41. 41.
    Kurth T, Glynn RJ, Walker AM, Rexrode KM, Buring JE, Stampfer MJ, Hennekens CH, Gaziano JM. Analgesic use and change in kidney function in apparently healthy men. Am J Kidney Dis 2003; 42(2): 234-44.PubMedGoogle Scholar
  42. 42.
    Curhan GC, Knight EL, Rosner B, Hankinson SE, Stampfer MJ. Lifetime nonnarcotic analgesic use and decline in renal function in women. Arch Intern Med 2004; 164(14):1519-24.PubMedGoogle Scholar
  43. 43.
    McLaughlin JK, Lipworth L, Chow W-H, Blot WJ. Analgesic use and chronic renal failure: A critical review of the epidemiologic literature. Kidney Int 1998; 54: 679-686.Google Scholar
  44. 44.
    Delzell E, Shapiro S. A review of epidemiologic studies of nonnarcotic analgesics and chronic renal disease. Medicine 1998; 77(2): 102-121.PubMedGoogle Scholar
  45. 45.
    Buckalew VM, Schey HM. Renal disease from habitual antipyretic analgesic consumption: an assessment of the epidemiologic evidence. Medicine 1986, 11: 291-303.Google Scholar
  46. 46.
    Elseviers M.M., De Broe M.E. Analgesic nephropathy: Is it caused by multi-analgesic abuse or single substance use ? Drug Safety 1999; 20(1): 15-24.PubMedGoogle Scholar
  47. 47.
    Gates TN, Temple AR. Analgesic use and chronic renal disease. N Engl J Med 1989; 321: 1125.CrossRefGoogle Scholar
  48. 48.
    McCredie M. Analgesic use and chronic renal disease. N Engl J Med 1989; 321: 1125.Google Scholar
  49. 49.
    Elseviers MM, De Broe ME. Epidemiology of analgesic nephropathy. J Nephrol 1992; 5: 94-98.Google Scholar
  50. 50.
    Elseviers MM, De Schepper A, Corthouts R, Bosmans JL, Cosyn L, Lins RL, Lornoy W, Matthys E, Roose R, Van Caesbroeck D, Waller I, Horackova M, Schwarz A, Svrcek P, Bonucchi D, Franek E, Morlans M, De Broe ME. High diagnostic perform ance of CT scan for analgesic nephropathy in patients with incipient to severe renal failure. Kidney Int 1995; 48: 1316-1323.PubMedGoogle Scholar
  51. 51.
    Elseviers MM, Bosteels V, Cambier P, De Paepe M, Godon JP, Lins R, Lornoy W, Matthys E, Moeremans C, Roose R, Theelen B, Van Caesbroeck D, Verbanck J, De Broe ME. Diagnostic criteria of analgesic nephropathy in patients with end-stage renal failure: results of the Belgian study. Nephrol Dial Transplant 1992; 7: 479-486.PubMedGoogle Scholar
  52. 52.
    Elseviers MM, Waller I, Nenov D, Levora J, Matousovic K, Tanquerel T, Pommer W, Schwarz A, Keller E, Thieler H, Köhler H, Le-moniatou H, Cresseri D, Bonucchi D, Fiocchi O, Jordans J, Franek E, Silva FJ, Fernandez Ruiz EJ, Morlans M, Hellström M, Wauters JP, Felle D, Cassi HV, De Broe ME. Evaluation of diagnostic criteria for analgesic nephropathy in patients with end-stage renal failure: results of the ANNE study. Nephrol Dial Transplant 1995; 10: 808-814.PubMedGoogle Scholar
  53. 53.
    Elseviers MM, De Broe ME. Combination analgesic involvement in the pathogenesis of analgesic nephropathy. Am J Kidney Dis 1996; 28(6): 958-962 (letter to the editor).Google Scholar
  54. 54.
    Noels LM, Elseviers MM, De Broe ME. Impact of legislative measures on the sales of analgesics and the subsequent prevalenceof analgesic nephropathy: a comparative study in France, Sweden and Belgium. Nephrol Dial Transplant 1995; 10: 167-174.PubMedGoogle Scholar
  55. 55.
    Chang SH, Mathew TH, McDonald SP. Analgesic Nephropathy and Renal Replacement Therapy in Australia: Trends, Comorbidities and Outcomes. Clin J Am Soc Nephrol 2008; 3: 768-776.Google Scholar
  56. 56.
    U.S. Renal Data System, USRDS 2007 Annual Data Report: Atlas of Chronic Kidney Disease and End-Stage Renal Disease in the United States, National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, MD, 2007.Google Scholar
  57. 57.
    Wing AJ, Brunner FP, Geerlings W, Broyer M, Brynger H, Fassbinder W, Rissoni G, Selwood NH, Tufveson G. Contribution of toxic nephropathies to end-stage renal failure in Europe: a report from the EDTA-ERA Registry. Toxicol Lett 1989; 46: 281-292.PubMedGoogle Scholar
  58. 58.
    Nanra RS. Analgesic nephropathy in the 1990’s: an Australian perspective. Kidney Int 1993; 42 (suppl 44): 86-92.Google Scholar
  59. 59.
    Stewart JH, McCredie M, Disney APS, Mathew TH. Trends in incidence of end-stage of end-stage renal failure in Australia, 19721991. Nephrol Dial Transpl 1994; 9: 1377-1382.Google Scholar
  60. 60.
    McAnally JF, Winchester JF, Schreiner GE. Analgesic nephropathy. An uncom mon cause of end-stage renal disease. Arch Intern Med 1983; 143: 1897-1899.PubMedGoogle Scholar
  61. 61.
    Gonwas TA, Hamilton RW, Buckalew VM. Chronic renal failure and end-stage renal disease in Northwest North Carolina. Importance of analgesic-associated nephropathy. Arch Intern Med 1981; 141: 462-465.Google Scholar
  62. 62.
    Wilson DR, Gault MH. Declining incidence of analgesic nephropathy in Canada. Can Med Assoc J 1982; 127: 500-503.PubMedGoogle Scholar
  63. 63.
    Seedat YK, Naicker S, Rawat R, Parsoo I. Racial differences in the causes of end-stage renal failure in Natal. S Afr Med J 1984; 65: 956-958.PubMedGoogle Scholar
  64. 64.
    Segasothy M, Suleimam AB, Puvaneswary M, Rohana A. Paracetamol: a cause for analgesic nephropathy and end-stage renal disease. Nephron 1988; 50: 50-54.PubMedGoogle Scholar
  65. 65.
    Kantachuvesiri S, Kaojarern S, Kitayaporn D, Phanichphant S, Sumethkul V, Wananukul W, Pongskul C, Arkaravichien W, Jankriengkri S, Chanchairujira T. Risk factors between analgesic use and chronic nephropathy in Thailand. Southeast Asian J Trop Med Public Health 1996; 27(2): 350-355.PubMedGoogle Scholar
  66. 66.
    Matousovic K, Elseviers MM, Devecka D, Horackova M, Turek T, De Broe ME, and the Group of Czech and Slovak Nephrologists. Incidence of analgesic nephropathy among patients undergoing renal replacement therapy in Czech republic and Slovak republic. Nephrol Dial Transplant 1996; 11: 1048-1051.Google Scholar
  67. 67.
    Elseviers MM, De Broe ME. Is analgesic nephropathy still a problem in Bel gium ? Nephrol Dial Transplant 1988; 2: 143-149.Google Scholar
  68. 68.
    Matyus J, Ujhelyi L, Karpati I, Ben T, Kakuk G. Increase in the incidence of analgesic nephropathy in Hungary. Nephrol Dial Transplant 1997; 12(8): 1774-1775.PubMedGoogle Scholar
  69. 69.
    Franek E, Kokot F, Grzeszczak W, Gajos L. Is analgesic nephropathy a problem in the South-West Region of Poland ? Nephron 1996; 72: 353 (letter to the editor).PubMedGoogle Scholar
  70. 70.
    Bennett WM, De Broe ME. Analgesic nephropathy - a preventable renal disease. N Engl J Med 1989; 320: 1269-1271.PubMedCrossRefGoogle Scholar
  71. 71.
    Mihatsch MJ, Staehelin HB, Musfeld D, Perret E, Oberholzer M. Phenacetin-Abusus: Kardiovaskuläre Risikofactoren. Nieren Hochdruck 1983; 3: 83-92.Google Scholar
  72. 72.
    Ivey KJ. Gastrointestinal intolerance and bleeding with non-narcotic analgesics. Drugs 1986; 32(suppl 4): 71-89.PubMedGoogle Scholar
  73. 73.
    Laporte J-R, Carne X, Vidal X, Moreno V, Juan J. Upper gastrointestinal bleeding in relation to previous use of analgesics and non-steroidal anti-inflamma tory drugs. Lancet 1991; 337: 85-89.PubMedGoogle Scholar
  74. 74.
    Mihatsch MJ. Empfohlene Massnahmen zur Bekampfung des Analgetikamis brauchs. In: Das Analgetikasyndrom. Mihatsch MJ (editor). George Theme Verlag, Stuttgart 1986; p. 134-135.Google Scholar
  75. 75.
    Stewart JH. The analgesic syndrome. In: Analgesic and NSAID-induced kidney disease. Stewart JH (editor). Oxford University Press, Oxford 1993; p. 58-66.Google Scholar
  76. 76.
    Hultengren N, Lagergren C, Ljungqvist A. Carcinoma of the renal pelvis in renal papillary necrosis. Acta Chir Scand 1965; 130: 314-320.PubMedGoogle Scholar
  77. 77.
    Bengtsson U, Johansen S, Angervall L. Malignancies of the urinary tract and their relation to analgesic abuse. Kidney Int 1978; 13: 107-113.PubMedGoogle Scholar
  78. 78.
    Kliem V, Thon W, Krautzig S, Kolditz M, Behrend M, Pichlmayr R, Koch KM, Frei U, Brunkhorst R. High mortality from urothelial carcinoma despite regular tumor screening in patients with analgesic nephropathy after renal transplantation. Transpl Int 1996;  9: 231-235.Google Scholar
  79. 79.
    Mihatsch MJ, Manz T, Knüsli C, Hofer HO, Rist M, Guetg R, Rutishauser G, Zollinger HU. Phenace tinabusus III. Maligne Harnwegtumoren bei Phenacetina busus in Basel 1963-1977. Schweiz Med Wschr 1980; 110: 255-264.PubMedGoogle Scholar
  80. 80.
    McCredie M, Ford JM, Stuart Taylor J, Stewart JH. Analgesics and cancer of the pelvis in New South Wales. Cancer 1982; 49: 2617-2625.PubMedGoogle Scholar
  81. 81.
    Lornoy W, Becaus I, Morelle V, Fonteyne E. Néphropathies chroniques par abus d’analgésiques: fréquence, pathogenèse, aspects cliniques, développement de tumeurs malignes. In: Séminaires d’uro-néphrologie. Chatelain C (editor). Masson, Paris 1988; p. 99-105.Google Scholar
  82. 82.
    Blohme I, Johansson S. Renal pelvic neoplasms and atypical urothelium in patients with end-stage analgesic nephropathy. Kidney Int 1981; 20(5): 671-675.PubMedGoogle Scholar
  83. 83.
    McCredie M, Stewart JH, Carter JJ, Turner J, Mahony JF. Phenacetin and papillary necrosis: independent risk factors for renal pelvic cancer. Kidney Int 1986; 30(1): 81-84.PubMedGoogle Scholar
  84. 84.
    Kincaid-Smith P. Renal toxicity of non-narcotic analgesics. At-risk patients and prescribing applications. Med Toxicol 1986; 1 (suppl 1): 14-22.PubMedGoogle Scholar
  85. 85.
    Gloor FJ. Changing concepts in pathogenesis and morphology of analgesic nephropathy as seen in Europe. Kidney Int 1978; 13: 27-33.PubMedGoogle Scholar
  86. 86.
    Murray RM. Genesis of analgesic nephropathy in the United Kingdom. Kidney Int 1978; 13: 50-57.PubMedGoogle Scholar
  87. 87.
    Schwarz A, Faber U, Borner K, Keller F, Offerman G, Molzahn M. Reliability of drug history in analgesic users. Lancet 1984; 2:1163-1164.PubMedGoogle Scholar
  88. 88.
    Henrich WL, Clark RL, Kelly JP, Buckalew VM, Fenves A, Finn WF, Shapiro JI, Kimmel PL, Eggers P, Agodoa LE, Porter GA, Shapiro S, Toto R, Anderson T, Cupples LA, Kaufman DW. Non-contrast-enhanced computerized tomography and analgesic-related kidney disease: report of the national analgesic nephropathy study. J Am Soc Nephrol 2006; 17(5):1472-80.PubMedGoogle Scholar
  89. 89.
    Elseviers MM, De Broe ME. Analgesic nephropathy in Belgium is related to the sales of particular analgesic mixtures. Nephrol Dial Transplant 1994; 9: 41-46.PubMedGoogle Scholar
  90. 90.
    Kincaid-Smith P. Analgesic nephropathy in Australia. Contrib Nephrol 1979; 16: 57-64.PubMedGoogle Scholar
  91. 91.
    Nanra RS, Kincaid-Smith P. Experimental evidence for nephrotoxicity of anal gesics. In: Analgesic and NSAID-induced kidney disease. Stewart JH (editor). Oxford University Press, Oxford 1993, p. 17-31Google Scholar
  92. 92.
    von Mühlendahl KE. Nephritis durch 5-aminosolicylsäure. Deutsch Med Wschr 1989; 114: 236.PubMedGoogle Scholar
  93. 93.
    Henning HV, Meinhold J. Chronische interstitielle nephritis durch 5-aminosalicyl säure ? Deutsch Med Wsch 1989; 114: 1091.Google Scholar
  94. 94.
    Ruf-Ballauf W, Hofstädter F, Krentz K. Acute interstitielle nephritis durch 5-aminosalicylsäure ? Internist 1989; 30: 262-264.PubMedGoogle Scholar
  95. 95.
    Mehta RP. Acute interstitial nephritis due to 5-aminosalicylic acid. Can Med Assoc J 1990; 143(10): 1031-1032.Google Scholar
  96. 96.
    Masson EA, Rodhes JM. Mesalazine associated nephrogenic diabetes insipidus presenting as weight loss. Gut 1992; 33: 563-4.PubMedGoogle Scholar
  97. 97.
    Thuluvath PJ, Ninkovic M, Calam J, Anderson M. Mesalazine induced interstitial nephritis. Gut 1994; 35: 1493-1496.PubMedGoogle Scholar
  98. 98.
    Smilde TJ, van Liebergen FJHM, Koolen MI, Gerlag PGG, Assmann KJM, Berden JHM. Tubulo-interstitiële nefritis door mesalazine (5-ASA)-preparaten. Ned Tijdschr Geneesk 1994; 138: 2557-2561Google Scholar
  99. 99.
    Calvino J, Romero R, Pintos E, Losada E, Novoa D, Güimil D, Mardaras J, Sanchez-Guisande D. Mesalazine-associated tubulointerstitial nephritis in inflammatory bowel disease. Clin Nephrol 1998; 49(4): 265-257.PubMedGoogle Scholar
  100. 100.
    Gisbert JP, Gonzalez-Lama Y, Maté J. 5-Aminosalicylates and renal function in inflammatory bowel disease: a systematic review. Inflamm Bowel Dis 2007; 13(5): 629-638.Google Scholar
  101. 101.
    Muller AF, Stevens PE, Mcintyre AS, Ellison H, Logans RF. Experience of 5-aminosalicylate nephrotoxicity in the United Kingdom. Aliment Pharmacol Ther 2005; 21: 1217-1224.PubMedGoogle Scholar
  102. 102.
    Schreiber S, Hämling J, Zehnter E, Howaldt S, Daerr W, Raedler A, Kruis W. Renal tubular dysfunction in patients with inflammatory bowel disease treated with aminosalicylate. Gut 1997; 40: 761-766.PubMedGoogle Scholar
  103. 103.
    Herrlinger KR, Noftz MK, Fellermann K, Schmidt K, Steinhoff J, Stange EF. Minimal renal dysfunction in inflammatory bowel disease is related to disease activity but not to 5-ASA use. Aliment Pharmacol Ther 2001; 15: 363-369.PubMedGoogle Scholar
  104. 104.
    Poulou AC, Goumas KE, Dandakis DC, Tyrmpas I, Panagiotaki M, Georgouli A, Soutos D, Archimandritis A. Microproteinuria in patients with inflammatory bowel disease: is it associated with the disease activity or the treatment with 5-aminosalicylic acid? World J Gastroenterol 2006; 12(5): 739-746PubMedGoogle Scholar
  105. 105.
    Elseviers M.M., De Broe M.E., the 5-ASA-Study Group. Risk of chronic interstitial nephritis in patients with inflammatory bowel disease treated with 5-ASA therapy. J Am Soc Nephrol 11: 128A, 2000.Google Scholar
  106. 106.
    Elseviers MM, D’Haens G, Lerebours E, Plane C, Stolear JC, Riegler G, Capasso G, Van Outryve M, Mishevska-Mukaetova P, Djuranovic S, Pelckmans P, De Broe ME, for the 5-ASA study group. Renal impairment in patients with inflammatory bowel disease: association with aminosalicylate therapy? Clin Nephrol 2004; 61(2): 83-91.Google Scholar
  107. 107.
    Calder IC, Funder CC, Green CR, Ham KN, Tange JD. Nephrotoxic lesions from 5-aminosalicylic acid. Brit Med J 1972; 1: 152-154.PubMedGoogle Scholar
  108. 108.
    Calder IC, Funder CC, Green CR, Ham KN, Tange JD. Comparative toxicity of aspirin and phenacetin derivatives. Brit Med J 1971; 4: 518-521.PubMedGoogle Scholar
  109. 109.
    Dwarakanath AD, Michael J, Allan RN. Sulphasalazine induced renal failure. Gut 1992; 33: 1006-1007PubMedGoogle Scholar
  110. 110.
    Izzedine H, Simon J, Piette AM, Lucsko M, Baumelou A, Charitanski D, Kernaonet E, Baglin AC, Deray G, Beaufils H. Primary chronic interstitial nephritis in Crohn’s disease. Gastroenterology 2002; 123(5): 1436-1440.PubMedGoogle Scholar
  111. 111.
    Glickman RM. Inflammatory bowel disease (ulcerative colitis and Crohn’s disease). In: Harrison’s Principles of Internal Medicine (13th edition, volume 2). Isselbacher KJ, Braunwald E, Wilson JD, Martin JB, Fauci AS, Kasper DL (editors). McGraw-Hill, In, New York, p. 1403-1417.Google Scholar
  112. 112.
    Greenstein AJ, Janowitz HD, Sachar DB. The extra-intestinal complications of Crohn’s disease and ulcerative colitis: a study of 700 patients. Medicine 1976; 55(4): 401-412.PubMedGoogle Scholar
  113. 113.
    Moayyedi P, Fletcher S, Harnder P, Axon ATR, Brownjohn A. Mesangiocapill ary glomerulonephritis associated with ulcerative colitis: case report of two patients. Nephrol Dial Transplant 1995; 10: 1923-1924.PubMedGoogle Scholar
  114. 114.
    Wilcox GM, Aretz HT, Roy MA, Roche JK. Glomerulonephritis associated with inflammatory bowel disease. Gastroenterology 1990; 98: 786-791.PubMedGoogle Scholar
  115. 115.
    Järnerot G. New salicylates as maintenance treatment in ulcerative colitis. Gut 1994; 35: 1155-1158.PubMedGoogle Scholar
  116. 116.
    Clemett D, Markham A. Prolonged-release mesalazine: a review of its therapeutic potential in ulcerative colitis and Crohn’s disease. Drugs 2000; 59(4): 929-956.PubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2008

Authors and Affiliations

  • Monique M. Elseviers
    • 1
  • Marc E. De Broe
    • 1
  1. 1.Faculty of Medicine Universiteitsplein 1University of AntwerpBelgium

Personalised recommendations